Company intelligence / Profile preview

Bellerophon Therapeutics

Warren, New Jersey, United Statesorpha.net ↗

Ownership: Private
Employees: ~18
Development stage: Phase 3

Overview

Bellerophon’s lead program was the INOpulse® platform for targeted delivery of inhaled nitric oxide in various forms of pulmonary hypertension. The company’s pivotal Phase 3 REBUILD trial in fibrotic interstitial lung disease did not meet its primary endpoint but confirmed safety and tolerability. Other programs include completed or ongoing studies in PAH and PH-COPD. The Bioabsorbable Cardiac Matrix device failed to show efficacy in a large Phase 3 study for preventing heart failure after myocardial infarction[6][7][10].

Therapeutic areas: PulmonologyCardiovascular
Modalities: Nitric oxide (gaseous therapeutic)drug-device combination productsimplantable medical devices
Industry: Biotech

Drug pipeline

1 asset

iNO45

Discontinued

Partnerships

Exclusive worldwide rights to develop/commercialize INOpulse from Ikaria, Inc.[1]Exclusive worldwide license to BCM from BioLineRx Ltd.[1]

Beyond the preview

Go deeper on Bellerophon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bellerophon Therapeutics.

Explore the full profile